Q1 2024 EPS Estimates for Oncternal Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:ONCT)

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) – Equities research analysts at HC Wainwright lifted their Q1 2024 earnings estimates for Oncternal Therapeutics in a research note issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($3.30) per share for the quarter, up from their previous estimate of ($3.52). HC Wainwright currently has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Oncternal Therapeutics’ current full-year earnings is ($12.03) per share. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q2 2024 earnings at ($3.42) EPS, Q3 2024 earnings at ($3.63) EPS, Q4 2024 earnings at ($3.68) EPS and FY2024 earnings at ($14.04) EPS.

Oncternal Therapeutics (NASDAQ:ONCT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.09) by ($0.02). The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. During the same period in the previous year, the company posted ($4.00) EPS.

Separately, StockNews.com started coverage on shares of Oncternal Therapeutics in a research report on Wednesday. They set a “hold” rating for the company.

Oncternal Therapeutics Stock Performance

Shares of ONCT opened at $8.60 on Thursday. The company has a market capitalization of $23.13 million, a price-to-earnings ratio of -0.64 and a beta of 1.26. The company’s 50 day simple moving average is $8.90 and its 200 day simple moving average is $8.11. Oncternal Therapeutics has a 1 year low of $5.57 and a 1 year high of $13.14.

Insider Buying and Selling

In related news, Director Robert James Wills purchased 6,914 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was purchased at an average price of $8.48 per share, with a total value of $58,630.72. Following the completion of the transaction, the director now owns 6,914 shares of the company’s stock, valued at approximately $58,630.72. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders purchased 10,714 shares of company stock valued at $92,736. Insiders own 8.00% of the company’s stock.

Institutional Investors Weigh In On Oncternal Therapeutics

Several large investors have recently made changes to their positions in ONCT. Citadel Advisors LLC acquired a new stake in shares of Oncternal Therapeutics in the fourth quarter worth $29,000. Prudential Financial Inc. acquired a new stake in shares of Oncternal Therapeutics in the second quarter worth $32,000. Mirabella Financial Services LLP acquired a new stake in shares of Oncternal Therapeutics in the first quarter worth $38,000. Virtu Financial LLC acquired a new stake in shares of Oncternal Therapeutics in the second quarter worth $48,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Oncternal Therapeutics in the first quarter worth $99,000. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.